HC Wainwright & Co. Assumes Insmed at Buy, Announces Price Target of $220
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. analyst Matthew Caufield assumes Insmed (NASDAQ:INSM) with a Buy rating and announces Price Target of $220.
HC Wainwright & Co. analyst Matthew Caufield assumes Insmed (NASDAQ:INSM) with a Buy rating and announces Price Target of $220.